Seattle Genetics (SGEN -0.9%) announces that its cancer medicine Adcetris performed well when...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN -0.9%) announces that its cancer medicine Adcetris performed well when combined with more established treatments in a phase I trial on advanced stage Hodgkin lymphoma patients. The firm says it will now move forward with a phase III clinical trial based on the positive results.